143 related articles for article (PubMed ID: 16863481)
21. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
22. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.
Lin YS; Lockwood GF; Graham MA; Brian WR; Loi CM; Dobrinska MR; Shen DD; Watkins PB; Wilkinson GR; Kharasch ED; Thummel KE
Pharmacogenetics; 2001 Dec; 11(9):781-91. PubMed ID: 11740342
[TBL] [Abstract][Full Text] [Related]
23. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
24. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
25. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics.
Penzak SR; Acosta EP; Turner M; Edwards DJ; Hon YY; Desai HD; Jann MW
J Clin Pharmacol; 2002 Oct; 42(10):1165-70. PubMed ID: 12362932
[TBL] [Abstract][Full Text] [Related]
26. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
28. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
Plosker GL; Scott LJ
Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
[TBL] [Abstract][Full Text] [Related]
29. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
Pai MP; Schriever CA; Diaz-Linares M; Novak RM; Rodvold KA
Pharmacotherapy; 2004 May; 24(5):592-9. PubMed ID: 15162893
[TBL] [Abstract][Full Text] [Related]
30. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
[TBL] [Abstract][Full Text] [Related]
32. Indinavir concentrations and antiviral effect.
Acosta EP; Henry K; Baken L; Page LM; Fletcher CV
Pharmacotherapy; 1999 Jun; 19(6):708-12. PubMed ID: 10391416
[TBL] [Abstract][Full Text] [Related]
33. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
34. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
Usansky HH; Hu P; Sinko PJ
Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
[TBL] [Abstract][Full Text] [Related]
35. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
36. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers.
Kakuda TN; Falcon RW
Pharmacotherapy; 2006 Aug; 26(8):1060-8. PubMed ID: 16863482
[TBL] [Abstract][Full Text] [Related]
37. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
[TBL] [Abstract][Full Text] [Related]
38. Effects of St. John's wort extract on indinavir pharmacokinetics in rats: differentiation of intestinal and hepatic impacts.
Ho YF; Huang DK; Hsueh WC; Lai MY; Yu HY; Tsai TH
Life Sci; 2009 Aug; 85(7-8):296-302. PubMed ID: 19559714
[TBL] [Abstract][Full Text] [Related]
39. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]